Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Monk, I hope you’re half right ($12.50), at this point in time. Feel free to expand on your $25 price guess by 12/31/22
I am an appreciative board poster. Much respect for your efforts.
Perhaps that can be a new Raf poll. When exactly do we hear from KP about final Mitigate data?
A strong Mitigate read by poster D on Yahoo follows:
The unspoken elephant in the room is MITIGATE. Why this trial is ignored by every single analyst is a mystery. Not only should it show significant mitigation of COVID severity, but at trial end it will also confirm REDUCE-IT cardiovascular benefit, drawing to an end the long lasting mineral oil scam and push full adoption by skeptical agencies.. It might also expand Vascepa's treatment parameters for more heart disease patients, like no TG requirements, and even could reduce the chances of other respiratory disease, like the common cold. Unless you don't believe in the science of JELIS, REDUCE-IT, CHERRY, EVAPORATE and Cardio-Link, MITIGATE is destined to be exceptional. As far as April 3rd passing without a presentation by Kaiser, well, if MITIGATE was successful, there are the critics who'd question everything about the unusual trial design and confuse the message, like Feuerstein, Herper and Nissen pulled off 5 minutes after the 2018 AHA, a stench that remains to this day. A peer review is probably what Kaiser is waiting on, because they know an attack on Vascepa's results will also cast a shadow on their trial design and research acumen. The study is incredibly complex, with the one to ten treatment versus control arm ratio. It's even more daunting when you add in all the different patient CVD types, multiple COVID variants during the trial and different timelines for each patient getting vaccinations and boosters. Fertile territory for the enemies of Vascepa to attack. I strongly believe the trial will show statistical benefit, but even the best, most unassailable data, can be dirtied by the trolls that continue to attack Vascepa. That's why I believe April 3rd was called off, to answer all the FUD before it has any chance to stick.
Understood…I remember a post in 2Q ‘20 describing how a covid trial might just end up being a possible bonus in the Vascepa anti inflammatory portfolio. The time spent in Mitigate has been plenty and if more data scrutiny is/was needed, then that’s a good thing.
North, to clarify.. you were thinking of selling out of 100k BIEL “under water” shares valued at a total of $100.00?
What did you pay for all of them, $200 total?
So you’re on record that Mitigate data sucks and it’s going to be an anchor to share price when it’s released?
74321
Did Zach just give us a heads up to new AMRN patents filed that might bring us out of purgatory with the generics? Hence the recent Hikma issues seemingly settled?
I’m spit balling trying to “Matlock” this post from Silbersher posted by dogn
dogn, it’s definitely a term used repeatedly…Cardiometabolic… I appreciate your attention to this. Might we be eventually seeing a different usage of V for weight issues? One of the posters being presented at ACC by Preston Mason is Vascepa study regardless of “waist circumference.”
Hey honest Abe, glad to have rekindled so many emotions for you in my meaningless post. Seemed to have touched a nerve? Guard your 100 shares tight, and take that $10 as soon as we get it.
Whomever acquires us( that is my hope) their patience will have paid off. Look at how much more has been learned about Vascepa in the last 3.5 years and, yet, we’re only slightly higher in pps than the eventful 9/24/18 day!?
Give me 1/2 share of PFE for one AMRN and I’ll be more than satisfied
A very interesting review of Mitigate, due 2 weeks from today.
From “D” 24 minutes ago on Yahoo.
MITIGATE is not about therapy. It's about mitigating the effects of COVID after contracting the disease, (important to note those in the trial have been mostly vaccinated and boosted). This is for patients with heart disease, not just the REDUCE-IT population, a population 5 times the size of REDUCE-IT; no statin or triglyceride requirements. And not just to reduce the severity of symptoms from COVID, but also to prevent cardiovascular events stemming from complications of the disease. And not just COVID, but all respiratory tract diseases. Since new variants will almost certainly evade vaccines and natural immunity, protecting ones heart while also mitigating COVID in the future is incredibly appealing. One other point here. There is a lot of confusion over how many patients are actually in the study's treatment arm, 1500 to 3900? Knowing KP, they likely decided to add generic V patients in separate arms as they want to make sure prescribing the generic is cost effective too. MITIGATE might be the undoing of the generics in the US if those arms fail while brand succeeds, but that's just conjecture. April 3rd could be enormous.
Bolio, until all legal aspects (Healthnet and possible appeal against Hikma) are played out, imo we will not be seeing “authorized generic” anytime soon. Of course all that changes if we were to be under different ownership.
I have to think that CVS abandoning generic V will benefit us in the near term and subsequent quarterly numbers. New and older shareholders have to daily remind ourselves of the names BVF and Sarissa and their ownership stakes. At least for me it keeps the thoughts of having made a good investment decision warm and not frozen. Frozen was our stint of trading under a $1.00 for a few weeks 8 years ago.
Just like CVD isn’t going anywhere, the same is with C-19 and the long hauler effects of the virus. Maybe it’s not AMRN but another company that benefits expanded Vascepa use with beneficial Mitigate data. I’d have a hollow feeling about this stock if Sarissa’s 24M shares weren’t on the table. I find their investment very reassuring going forward. BVF is also most prominent, as well. As they say, follow the money.
Wowza, you post cryptic messages with the best of them.
Perhaps the chatter back in 2020 about V being effective for Covid patients will produce the goods after all with April’s late breaker Mitigate data?
Maybe it was easy to target them as their only coverage is in California? They are now changing names to Ambetter from Healthnet.
Here’s to hoping you and other recent and consistent posters never join the All AMRN Decade Bag Holder group.
In Denner and BVF I trust…take me out of my shares with a proper deal.
Rose, it’s beyond ironic that AMRN wins 1A years ago and basically goes mute ever since. I know it’s been said several times recently, but we’re in a much better place now with the trifecta of Denner, BVF, and BB.
I actually hate the “r” word also. It’s heard daily on CNBC by a guest or host. Worn out and lacking conviction is how I feel about that dreaded word. Nails to a chalkboard.
Thanks for your help and efforts these past months. I hope watching the HBO Carl Icahn doc is a sign of things to come for us investors
May you route them in your own Super Bowl next week
Stay out of it jester
Zip- it’s Hikma
Hey Monday QB. Feel free to factor in Rule 24/60 hearing 2 weeks from today and then Mitigate in April, as well as any upcoming pop up 13-D’s. And I don’t mean after the fact.
You really are myopic. The fed and AMRN are hardly related. Are you taking your pennies away forever?
Spot on Bid…Creepy is another good description that’s been posted about that No. Cal honk. He’s truly a legend in his own mind.
Whalatane- please repost your 12/19 sell details (even if you have to “correct as necessary”) as to refresh our memories and you have time away from taking a hike. And feel free to state how many shares for these transactions.
I’m going Kiwi on Kiwi. Tell us all how many shares you bought and now hold. Don’t be shy. We can handle either a few hundred shares or few thousand you astutely snagged yesterday.
A few posts this afternoon showed 463,000 shares purchased today at a $2.93 avg by Sarissa. Muy bueno. Keep scooping them up like Pac Man
A good Fixx song almost 40 years ago. Want to buy me out at $19.99 today?
“It’s the one constant in life-if you build something worth having, someone’s gonna try and take it.”
-Yellowstone S2E9 “Enemies by Monday”
How appropriate to a certain molecule we know.
Are you this far Marjac or beyond?
So you’re saying there’s a cabal of shares shorted pre 9/24/18 that are still holding on to possibly break even <$3.
They didn’t cover during the 100M share tirade end of March ‘20 @$4.00 that was flatlined the whole day and then dipped to $3.95?
There isn’t a big % of short shares today, correct? Admittedly it’s been a low volume play sandbox for too long, but this has been an events driven pps roller coaster since 9/24/18. TA didn’t order Reno and the 3 stooges. Poor judgment did.
Who’s the “poisonous troll” that released this AHA embargoed info today (3) days early?
Has early news like this ever moved the share price needle? Rhetorical question, I know. Answer: No
Thanks for post of another AMRN patent awarded today.
Nice to see management in net positive accumulation mode of shares dated 12/31 for recently posted Form 4’s
Raf, today’s news certainly merits filtering and re-reading certain items, as you did. Thankfully this decision was spit out after hours and gives smart people plenty of time to post their replies. When Novo on ST says it’s a positive what happened today, then things are looking up.
China approval and Marjac are upcoming next followed by Mitigate and more EU news?
Posters on Stocktwits report email responses from AMRN Investor Relations this afternoon.
I’m going to attribute the $.04 AH bump to Marjac news. Quad witching is now over. Time for a Santa rally into ‘22 and to continue towards 2/11/22.
I believe we reached our nadir for ‘21 this week.
As we all too painfully know, waiting for outside forces to potentially help the company pps has been a patience test. To not have to wait several months for OA, but now less than 60 days, is super fortunate.
I’m pretty sure your initial post today re: 24/60 OA date just set an official record # of replies. Deservedly so.
Keep “A Few Good Men” in your thoughts at OA and ask Hikma “ Did you order the cropped table?”
This news resets the “next 60-90 days will be interesting” clock. I’m sure your mind is now in full game mode. Have a great weekend counselor.
To all: how long is a quiet period good for?
No deal,IMO, will be done until we have China confirmation. That’s days or weeks away, allegedly. Plus, what type of deal would we all be happy with at these current prices? Let’s hope to see the climb we had this past February repeat again in a few more months, if not sooner, and then some real chirping about a possible deal.
The change in ownership structure that started out this year is still in play for the rest of the year and beyond, no?
Note: a poster on Stocktwits mentioned that it was a p code purchase. I have no clue what it means, but another poster commented that it is strategic and maybe not a “quiet period” concern?